



Daniele Piomelli, PhD, DVM Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry Louise Turner Arnold Chair in the Neurosciences University of California, Irvine Founding Director, Drug Discovery and Development Italian Institute of Technology



#### Andrew A. Monte, MD

Associate Professor Emergency Medicine & Medical Toxicology Departments of Emergency Medicine & Pharmaceutical Sciences University of Colorado Denver-Anschutz Medical Center & Rocky Mountain Poison & Drug Center Denver Health & Hospital Authority



George Kunos, MD, PhD Medical Scientist Bethesda, MD



#### David Casarett, MD, MA Professor of Medicine Chief of Palliative Medicine Duke University / Duke Health



Giovanni Marsicano, DVM, PhD Inserm Unit 862 "Physiopathology of Neuroplasticity" Inserm Avenir Team "Endocannabinoids and Neuroadaptation" NeuroCentre Magendie, Bordeaux - Inserm Unit 862



#### Pier Vincenzo Piazza, PhD Director of Inserm Unit 862 "Physiopathology of Neuroplasticity" Director of the Neurocentre Magendie, Bordeaux.

NeuroCentre Magendie, Bordeaux - Inserm Unit 862

Comparative Medicine eet, BML 330

Γ 06520-8016

of Medicine

al



and CT Pharmaceutical Solutions Present

# Medicin in. 6 annal

Saturday, November 12, 2016





Yale Comparative Medicine and CT Pharmaceutical Solutions Presents...

## **Cannabis in Medicine**

#### A CME Approved Course

### Saturday, November 12, 2016 8:00 am - 3:00 pm

Yale Comparative Medicine and CT Pharmaceutical Solutions Presents...

### **Cannabis in Medicine**

Yale School of Management 165 Whitney Avenue New Haven, CT 06511

Saturday, November 12, 2016 8:00 am - 3:00 pm

#### **Overview**

The medical use of marijuana has been approved in Connecticut and neighboring states. However, there is a lack of understanding in the medical community regarding the biological principles of ingredients of the cannabis plant at a systemic level. Also less well known is how the endogenous cannabinoid system present in humans and animal species may respond to herbal cannabis derivatives.

#### Learning Objectives

Upon completion of this program, participants should be able to identify:

- various tissues in the body that respond to cannabinoids.
- the possibilities how these biological mechanisms could be exploited in various aspects of medicine.

#### Who should attend This course is designed to address unmet needs for the practicing physician, nurse and PAs, as well as, the research community.

#### Directions

From New York to Pierson-Sage Garage: Get onto I-95N and after about 65 miles on I-95N, merge onto I-91N Take Exit 3 on I-91N for Trumbull St Turn right on Orange St Turn left on Humphrey St Pierson-Sage Garage will be on the end of the street.

From Hartford to Pierson-Sage Garage: Get onto I-91S Take exit 4 on I-91S for State St Turn right on Humphrey St Pierson-Sage Garage will be at end of the street.

From Pierson-Sage Garage to Yale SOM: With the garage behind you, turn right and walk down Whitney Avenue for 0.3 miles. The School of Management will be on your left.

Registration \$250 for MD's and Faculty Free for Residents and Fellows

RSVP by 11/1/2016 to: Susan Andranovich Susan.andranovich@Yale.edu On site payment via cash or check only. Checks made payable to Yale University.

Yale University is conveniently reached by Amtrak, Metro-North, Tweed Airport, and Bradley Airport

#### Saturday, November 12, 2016

8:00-8:45 am

3:00 pm

CME registration and continental Breakfast

:00-8:45 am	CME registration and continental breaklast
:00-9:15 am	Welcome - Tamas Horvath, PhD, DVM Yale University, Section of Comparative Medicine
:15-9:45 am	"Cannabis in Colorado: Lessons Learned" Andrew A. Monte, MD
:50-10:20 am	"Therapeutic potential of the cannabinoid system" Daniele Piomelli, PhD, MD (Hon)
0:20-10:40 am	Coffee Break
0:45-11:15 am	"The peripheral endocannabinoid system as a therapeutic target for metabolic diseases" George Kunos, MD, PhD
1:20-11:50 am	"A Doctor's Case for Medical Marijuana" David Casarett, MD, MA
2:00-1:00 pm	Lunch
:15-1:45 pm	"A Cannabinoid Link Between Mitochondria and Memory" Giovanni Marsicano, DVM, PhD
:50-2:20 pm	"CB1-Signaling Specific Inhibitors (SSi): a new pharmacological class derived by an endogenous modulator of the CB1 receptor" Pier Vincenzo Piazza, PhD
:30-3:00 pm	Round Table Discussion

**CLOSING REMARKS** 

Connecticut Pharmaceutical Solutions (CPS) is dedicated to advancing the understanding of medical marijuana use in clinical practice. CPS has allied with researchers at Yale University to provide a venue that highlights recent advancements in basic and clinical research of cannabis-related substances in biomedicine for practicing physicians in private and academic settings as well as for researchers.

With the legalization and availability of medical marijuana in Connecticut, practicing physicians are increasingly faced with questions from patients regarding the value of the use of cannabis for various illnesses. This symposium will provide an overview of cannabis research and provide information regarding emerging policies and issues in clinical settings.



#### **ACCREDITATION/DESIGNATION STATEMENT**

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of the The Yale School of Medicine, Section of Comparative Medicine, and CT Pharmaceutical Solutions. The Yale School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Yale School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credit<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **DISCLOSURE POLICY**

It is the policy of Yale University School of Medicine, through its Center for Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating in this symposium are required to disclose to the program audience any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.